In 1992, graduate student Yasumasa Ishida discovered PD-1, marking the beginning of a journey that would make this molecule a ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

Recent breakthroughs in understanding the prostaglandin D2 (PGD2) receptor 1 (DP1) are paving the way for innovative ...

Instil Bio eyes key NSCLC catalyst with Phase 2 China data in 2H 2025 and a distinct U.S. strategy. Learn why AXN-2510 stands ...

The global ablation technology market was valued at US$ 6.82 billion in 2024 and is projected to reach US$ 16.74 billion by ...

Background: The objective of this meta-analysis was to assess the effectiveness and safety of neoadjuvant PD-1/L1 inhibitors plus chemoradiotherapy(CRT) for locally advanced rectal cancer (LARC).

kDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands lDepartment of Biomedical Data Sciences, Section Molecular Epidemiology, Leiden University Medical ...

OX-4224 is an investigational oral small molecule that targets the PD-1/PD-L1 immune checkpoint pathway and offers a potentially more accessible and cost-effective option compared to existing ...

State Key Laboratory of Drug Research and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China ...

“This single receptor is responsible for our insatiable, never-ending attraction to sugar,” says Columbia neuroscientist Charles Zuker, who led the study. “And now that we have this ...

Programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF) are often co-expressed in the tumor microenvironment. The combination of anti-PD-1 and anti-VEGF agents has been ...